Cellectar Biosciences (CLRB) Q2 2024 earnings summary

Executive summary

• Pivotal trial data for iopofosine I 131 in Waldenstrom's macroglobulinemia (WM) showed strong efficacy in a highly refractory patient population, with results comparable to first- and second-line therapies despite being used as a fifth-line treatment, meeting primary and secondary endpoints with 80% ORR and up to 58.2% MRR.

• NDA submission for iopofosine in WM is planned for Q4 2024, with a potential six-month Priority Review and possible 2025 launch.

• The company is advancing additional studies in multiple myeloma, CNS lymphoma, pediatric high-grade gliomas, and mycosis fungoides, with updates and new trial initiations expected late 2024 or early 2025.

• Iopofosine has received multiple FDA designations, including Fast Track and Orphan Drug, and the company is leveraging its PDC platform for additional preclinical and partnered programs.

Financial highlights

• Cash and cash equivalents were $25.9 million as of June 30, 2024, up from $9.6 million at year-end 2023; $19.4 million was raised in July, extending the runway into Q2 2025.

• Net loss for H1 2024 was $27.6 million, with Q2 2024 net loss at $919,371; R&D expenses rose to $8.2 million for Q2 2024, and G&A expenses increased to $6.4 million.

• Net cash used in operating activities for Q2 2024 was approximately $14.1 million.

• Other income for Q2 2024 was $12,784,000, primarily from changes in warrant valuation.

Outlook and guidance

• Cash position, including July proceeds, is expected to fund operations into Q2 2025; management expects continued operating losses and significant cash use until product approval and commercialization.

• NDA submission for iopofosine in WM is targeted for Q4 2024, with a potential 6-month Priority Review and possible 2025 launch.

• Initial data from the pediatric high-grade glioma study is anticipated by year-end; phase I for the actinium-based solid tumor program and new mycosis fungoides trial are expected to start late 2024 or early 2025.